Skip to main navigation Skip to search Skip to main content

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

Stony Brook University

Project: Research

Project Details

StatusFinished
Effective start/end date11/29/22 → 04/13/25

Funding

  • Horizon Therapeutics Ireland DAC: $19,200.00